MDGL Earnings

Quarterly EPS
$-2.71
Q4 2024
$-2.61
Q1 2025
$-1.50
Q2 2025
$-4.01
Q3 2025
$-11.93
Q4 2025
$-3.25
Q1 2026
$-1.99
Q2 2026
$1.90
Q3 2026
Latest Revenue431.3M
Latest Net Income55.4M
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q3 2026$1.90431.3M55.4M+50.1%+147.4%
Q2 2026-$1.99364.3M-57939000+71.2%-32.7%
Q1 2026-$3.25311.3M-94391000+126.8%-24.5%
Q4 2025-$11.93321.1M-58575000+210.8%-340.2%
Q3 2025-$4.01287.3M-114190000+362.0%+18.5%
Q2 2025-$1.50212.8M-42281000+1,353.8%+78.9%
Q1 2025-$2.61137.3M-73238000—+64.6%
Q4 2024-$2.71103.3M-59416000—+52.2%
Q3 2024-$4.9262.2M-106964000——
Q2 2024-$7.1014.6M-151971000——
Q1 2024-$7.380-147541000——
Q4 2023-$5.670-112194000——
Madrigal Pharmaceuticals (MDGL) — Earnings